<DOC>
	<DOCNO>NCT00875667</DOCNO>
	<brief_summary>To evaluate safety efficacy lenalidomide versus investigator choice patient relapse refractory Mantle Cell Lymphoma .</brief_summary>
	<brief_title>A Study Determine Efficacy Lenalidomide Versus Investigator 's Choice Patients With Relapsed Refractory Mantle Cell Lymphoma ( MCL )</brief_title>
	<detailed_description>This research study patient relapse refractory mantle cell lymphoma follow treatment radiotherapy , immunotherapy , chemotherapy , radioimmunotherapy . Currently , clearly recommended standard treatment population . Chemotherapy agent gemcitabine , cytarabine , chlorambucil , fludarabine , immunotherapeutic agent , rituximab , may propose . Thus , aim search new treatment may improve prognosis patient relapse mantle cell lymphoma . The present clinical study aim determine lenalidomide safe active patient mantle cell lymphoma refractory treatment relapse , twice three time . Enrollment goal meet March 7th 2013 thus enrollment stop .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Biopsy proven mantle cell lymphoma Patients refractory regimen relapse , twice three time document progressive disease Eastern Cooperative Oncology Group ( ECOG ) performance score 0,1 , 2 Willing follow pregnancy precaution Any follow laboratory abnormality Absolute neutrophil count ( ANC ) &lt; 1,500 cells/mm^3 ( 1.5 x 10^9/L ) Platelet count &lt; 60,000/mm^3 ( 60 x 10^9/L ) Serum aspartate transaminase/Serum glutamic oxaloacetic transaminase ( AST/SGOT ) Alanine transaminase/Serum glutamic pyruvic transaminase ( ALT/SGPT ) &gt; 3.0 x upper limit normal ( ULN ) , except patient document liver involvement lymphoma Serum total bilirubin &gt; 1.5 x ULN , except case Gilbert 's Syndrome document liver involvement lymphoma . Calculated creatinine clearance ( CockcroftGault formula ) &lt; 30 mL/min History active central nervous system ( CNS ) lymphoma within previous 3 month Subjects willing take Deep venous thrombosis ( DVT ) prophylaxis Known seropositive active viral infection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) . Patients seropositive hepatitis B virus vaccine eligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>Relapsed Mantle Cell Lymphoma</keyword>
	<keyword>Refractory Mantle Cell Lymphoma</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>MCL</keyword>
</DOC>